Ultragenyx Pharmaceutical Inc’s recent filing unveils that its EVP and Chief Medical Officer Crombez Eric unloaded Company’s shares for reported $20405.0 on May 05 ’25. In the deal valued at $39.24 per share,520 shares were sold. As a result of this transaction, Crombez Eric now holds 71,530 shares worth roughly $2.65 million.
Then, Crombez Eric sold 242 shares, generating $8,497 in total proceeds. Upon selling the shares at $35.11, the EVP and Chief Medical Officer now owns 71,680 shares.
Before that, Horn Howard sold 1,785 shares. Ultragenyx Pharmaceutical Inc shares valued at $72,114 were divested by the Chief Financial Officer at a price of $40.40 per share. As a result of the transaction, Horn Howard now holds 106,169 shares, worth roughly $3.94 million.
William Blair initiated its Ultragenyx Pharmaceutical Inc [RARE] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in early June from “a Neutral” to “a Buy”. RBC Capital Mkts began covering RARE with “an Outperform” recommendation on April 22, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated RARE as “an Overweight”.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] saw its stock fall -1.01% to $37.11. Over the last five days, the stock has gained 0.19%. Ultragenyx Pharmaceutical Inc shares have fallen nearly -11.79% since the year began. Nevertheless, the stocks have fallen -16.87% over the past one year. While a 52-week high of $60.37 was reached on 02/06/25, a 52-week low of $29.59 was recorded on 04/09/25.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 36.35, which if violated will result in even more drops to 35.59. On the upside, there is a resistance level at 37.89. A further resistance level may holdings at 38.66.
